Source: Virtual Congress 2021 – Lung disease burden and management



Rating:

Share or cite this content

Citations should be made in the following way:
B. Stanley (One Shenton, Singapore), J. Chapaneri (Cambridge, United Kingdom), T. Tran (Gaithersburg, United States of America), E. Maslova (Cambridge, United Kingdom), V. Carter (One Shenton, Singapore), D. Price (One Shenton, Singapore). Late Breaking Abstract - Oral corticosteroid (OCS) risk predictor for osteoporosis. 2159

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract - Short-term and maintenance oral corticosteroid use for German patients with asthma Source: International Congress 2019 – Powerful cohort studies with/without lung function Year: 2019 Late Breaking Abstract - The burden of intermittent oral corticosteroid use in asthma Source: Virtual Congress 2021 – Asthma treatment: clinical and translational science Year: 2021 Late Breaking Abstract - Use of inhaled corticosteroids and the risk of lung cancer, the HUNT study Source: International Congress 2017 – Lung cancer - basic science: the latest results from the bench Year: 2017 Late Breaking Abstract - Overuse of oral corticosteroids in asthma – modifiable factors and potential role of biologics Source: International Congress 2019 – Novel findings from asthma clinical trials Year: 2019 Late Breaking Abstract - Exacerbation of asthma in childhood: seasonal pattern and risk factors. Source: International Congress 2017 – Paediatric asthma: therapies and comorbidities Year: 2017 Late Breaking Abstract - SABA overuse and risk of mortality in a nationwide Swedish asthma cohort (HERA) Source: International Congress 2019 – New towards old therapies in airway diseases Year: 2019 Late Breaking Abstract - Efficacy of oral prednisolone in patients with stable severe eosinophilic asthma (SEA) treated with Mepolizumab Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Late Breaking Abstract - Overestimation of asthma control and misperception of short-acting ß2-agonists (SABA) use among physicians in Poland Source: Virtual Congress 2020 – Prediction of outcomes in obstructive diseases Year: 2020 Late Breaking Abstract - Corticosteroid optimisation in severe asthma using composite biomarkers to adjust dose versus a symptom/risk-based algorithm Source: Virtual Congress 2020 – ALERT: Asthma in adults and children Year: 2020 Late Breaking Abstract - Oral corticosteroids exposure in a Swedish nationwide asthma population during 2006-2016 Source: International Congress 2018 – Does asthma phenotyping improve treatment? Year: 2018 Late Breaking Abstract - Two-year cumulative oral corticosteroid exposure in severe eosinophilic asthma before and after anti-IL-5 therapy Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021 Late Breaking Abstract - Factors associated with health-status of COPD patients on Dry Powder Inhaler (DPI) maintenance therapy Source: Virtual Congress 2021 – Highlights for primary care in 2021 Year: 2021 Late Breaking Abstract - Daily physical activity in patients with severe asthma and the effect of anti-IL5 therapy. Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Late Breaking Abstract - Compare outcomes between COPD patients treated with Tiotropium/Olodaterol (TIO/OLO) and other fixed-dose LAMA/LABAs Source: Virtual Congress 2020 – COPD and the impact of comorbidities Year: 2020 Late Breaking Abstract - Durable clinical benefit of benralizumab following oral corticosteroid reduction: The PONENTE study Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments Year: 2021 Late Breaking Abstract - Adrenal function improvement after oral corticosteroid reduction in benralizumab-treated severe eosinophilic asthma: PONENTE maintenance phase Source: Virtual Congress 2021 – Biomarkers to phenotype asthma: prediction of exacerbations Year: 2021 Late Breaking Abstract - Impact of maintenance and reliever therapy (MART)-focused asthma guideline on SABA prescriptions Source: Virtual Congress 2021 – Highlights for primary care in 2021 Year: 2021 Osteoporosis and fracture risk associated with inhaled corticosteroid use among Swedish COPD patients: the ARCTIC study Source: Eur Respir J, 57 (2) 2000515; 10.1183/13993003.00515-2020 Year: 2021 Late Breaking Abstract - Difference in clinical outcomes between smoking and non-smoking asthma patients who initiated an ICS or ICS/LABA treatment Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies Year: 2019 Late Breaking Abstract - Treatment with ATYR1923 reduces biomarkers in COVID-19 pneumonia Source: Virtual Congress 2021 – Diagnosis and management of COVID-19 Year: 2021